Glycemic Outcomes During Real-World Hybrid Closed-Loop System Use by Individuals With Type 1 Diabetes in the United States
Authors' conclusion
Real-world HCL system use in the U.S. demonstrated overall glycemic control that trended similarly with the system pivotal trial outcomes and previous real-world system use analyses.
Study context
- Population
- Individuals aged ≥7 years with T1D in the United States using the MiniMed 670G system with ≥10 days of CGM data after initiating Auto Mode; data uploaded to Carelink March 2017–November 2020overall cohort
- Participants
- 123,355 individuals
- Exposure
- Post- vs pre-Auto Mode initiation of MiniMed 670G hybrid closed-loop (HCL) system
- Outcome
- Glycemic outcomes post-Auto Mode initiation:
- Overall cohort
- Mean 87.9% of time in Auto Mode
- Follow-up
- Post-Auto Mode initiation
Methodological detailsreal-world, voluntarily uploaded device data
- Real-world
- Voluntarily uploaded device data
Main finding
As reported in the abstract
Glucose management indicator (GMI) (mean ± SD)
7.0% ± 0.4%
TIR (mean ± SD)
70.4% ± 11.2%
TBR <70 mg/dL (mean ± SD)
2.2% ± 2.1%
TAR >180 mg/dL (mean ± SD)
27.5% ± 11.6%
Observational data: associations, not effects.
Further findings
GMI, pre vs post Auto Mode (N = 52 941; 88.6% of time in Auto Mode) · decreased
P < 0.001
TIR, pre vs post Auto Mode · increased
P < 0.001
TAR >180 mg/dL, pre vs post Auto Mode · decreased
P < 0.001
| Outcome | Post-Auto Mode | Pre-Auto Mode | P value |
|---|---|---|---|
| TBR <70 mg/dL, pre vs post Auto ModeDecreased | 2.07 ± 2.25% % | 2.11 ± 2.4 | P = 0.002 |
Baseline GMI subgroups
- Baseline GMI <7.0%: TIR unchanged
- 77.4% ± 7.4% to 77.5% ± 8.0%, P = .456
- Baseline GMI <7.0%: TAR >180 mg/dL increased
- 19.2 ± 6.7 to 19.6 ± 7.9%, p < 0.001
- Baseline GMI >8.0%: all metrics statistically improved
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →